The use of liposomes as carriers of adriamycin (ADM) seems to offer important advantages with regard to the attenuation of the dose-dependent anthracycline-induced cardiomyopathy. This effect has been shown in rodents (Rahman et al., 1980(Rahman et al., , 1982 Forssen & Tokes, 1981; Olson et al., 1982) and dogs (Herman et al., 1983) and is apparently related at least partially to the reduced uptake of the drug in the cardiac tissue of animals treated with liposome-entrapped ADM (L-ADM) (Forssen & Tokes, 1979 , 1983 Rahman et al., 1980; Gabizon et al., 1982 Gabizon et al., , 1983 Olson et al., 1982) . Obviously, if this delivery system is to be useful therapeutically, it is crucial to evaluate its anti-tumour activity. Since liposomes home preferentially in tissues with sinusoidal capillaries and rich in cells of the reticuloendothelial system, such as the liver and spleen (Segal et al., 1974; Poste et al., 1982) , it is reasonable to assume that tumour colonies residing in these organs constitute a suitable target for liposome-mediated delivery of cytotoxic drugs. The purpose of this paper is to describe the antitumour In previous studies we showed that liposomes containing negatively charged phospholipids capture ADM very efficiently and cause important changes in the tissue distribution of the drug, viz. decreased levels in the heart and increased and sustained levels in the liver and spleen. These changes were observed in normal (Gabizon et al., 1982) and in tumour-bearing mice (Gabizon et al., 1983) . Furthermore, when metastatic tumour cells were isolated from the liver we found significantly higher intracellular levels of ADM in tumour cells of mice treated with L-ADM as compared to free ADM treatment. Also, the proliferative ability of intrahepatic metastatic cells in in vitro qultures and in vivo transfer assays was markedly more impaired after L-ADM treatment than after ADM alone (Gabizon et al., 1983) .
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In previous studies we showed that liposomes containing negatively charged phospholipids capture ADM very efficiently and cause important changes in the tissue distribution of the drug, viz. decreased levels in the heart and increased and sustained levels in the liver and spleen. These changes were observed in normal (Gabizon et al., 1982) and in tumour-bearing mice (Gabizon et al., 1983) . Furthermore, when metastatic tumour cells were isolated from the liver we found significantly higher intracellular levels of ADM in tumour cells of mice treated with L-ADM as compared to free ADM treatment. Also, the proliferative ability of intrahepatic metastatic cells in in vitro qultures and in vivo transfer assays was markedly more impaired after L-ADM treatment than after ADM alone (Gabizon et al., 1983) .
These results, and especially the ability of liposomes to increase the intracellular levels of ADM in liver-residing tumour cells, provided a rational basis for therapeutic experiments. In the present study, we have compared the survival of tumour-inoculated mice treated either with L-ADM or with free ADM using the metastatic liver model of the J-6456 lymphoma. Our results suggest that the therapeutic index of ADM can be significantly improved by liposome association in a group of selected neoplastic processes and emphasize the potential usefulness of this approach. Some of our initial observations on therapeutic studies with the J-6456 lymphoma have been previously reported (Gabizon et al., 1982) .
Materials and methods
Animals and tumour Age-and sex-matched BALB/c mice from the Animal Breeding Center of the Hebrew University (Jerusalem, Israel) were used in these experiments. Tumour cells were obtained from a BALB/c, radiation-induced, T-cell derived lymphoma (J-6456) described previously (Gabizon & Trainin, 1980 (Gabizon et al., 1982) . Briefly, 50-65% of the initial amount of ADM was retained in the liposomes using a 3:7 molar ratio of either phosphatidylserine (PS): phosphatidylcholine (PC) or phosphatidylglycerol (PG): PC, respectively. The final molar ratio of ADM to phospholipids in the vesicles was -12%. Liposomes were stored at 4°C in sterile, siliconized, vacuum-sealed tubes (Vacutainer Systems, Rutherford, NJ) protected from light. Liposomes were used within 3 weeks after storage. Mice given injections of free ADM received freshly prepared drug solutions.
Histological examinations Light microscopy examinations were performed in organs from tumour-inoculated mice with and without treatment. Liver, spleen, and kidneys were fixed in Bouin's solution and stained with haematoxylin-eosin-phosphomolybdic acid: light green stain. For details of the staining procedure see Levi-Schaffer et al. (1982) .
Statistical analysis
The statistical significance of the results was evaluated by the non-parametric, ranking test of Wilcoxon. Table I is that increasing the number of treatments from 3 to 4 and 5 injections did not further improve the antitumour effects observed. A rough evaluation of the relative efficacies of these two modalities of treatment can be inferred from our data on the growth kinetics of the J-6456 lymphoma shown in Figure 1 . Since the log growth time of this tumour is 5 days, and the differences in mean and median survivals between free ADM-treated and L-ADMtreated mice of experiments 1 to 5 were > 10 days, the estimated cytoreductive effect of L-ADM in this tumour model is 100 times higher than that of free ADM. Exceptionally there were long-term survivors with no macroscopic tumour recognizable at autopsy among L-ADM treated mice only. Association of ADM with liposomes was required for the enhancement of the anti-tumour effect to occur. As shown in Figure 2 , free ADM injected together with plain liposomes (mixed immediately before injection) was not more effective than free ADM alone. This indicates that simultaneous administration of the drug with plain liposomes does not lead to a synergistic anti-tumour effect.
We also investigated the effects of reducing the Chol content of the liposomes and of substituting PS by PG as the negatively-charged lipid component. The results of this experiment are presented in Figure 3 . Decreasing the Chol:phospholipid molar ratio from 100% to 25% did not cause any change in the in vivo anti-tumour activity of the ADM-loaded liposomes. The survival curves shown in Figure 3 also indicate that there was no significant difference in the anti-tumour activity using either PS or PG liposomes. This finding is in agreement with the results obtained in Table I in separate experiments.
In Figure 4 , we compare the anti-tumour effect of maximally tolerated doses of free ADM in single bolus injection to an equivalent dose of L-ADM. Using a dose of 12mgkg-1 of free ADM, a certain degree of toxicity is seen (-LD 10). With the same dose of L-ADM, no toxicity was observed and the anti-tumour effect was superior to the toxic dose (12mgkg-1) and to the maximally tolerated dose (l0mgkg-1) of free ADM.
The therapeutic effects of L-ADM and free ADM were compared also on locally growing tumours obtained by i.m. inoculation of the J-6456 lymphoma. Mice received 106 tumour cells i.m. into the thigh and were treated i.v. with 8mgkg-' of either free ADM or L-ADM on days 3, 10 and 17 after tumour inoculation. Median survivals were 22.0 (s.d. = 3.3), 28.6 (s.d. = 1.5), and 36.0 (s.d.=7.9) days respectively for untreated, L-ADM treated and free ADM treated mice. The differences between untreated and L-ADM treated, on the one hand, and between L-ADM treated and free ADM treated, on the other hand, were both statistically significant at the P <0.01 level (Wilcoxon test). Thus clearly, free ADM was more effective than an equal dose of L-ADM against tumour cells growing locally in the i.m. site, while the superior antitumour effect of L-ADM was expressed on tumours located in selected anatomic areas such as liver and spleen.
Histopathological study An anti-tumour experiment was conducted for the purpose of histopathological observations on tumour growth and response to treatment. Mice were inoculated i.v. with 106 J-6456 tumour cells and 10 days later treated with either free or liposome-entrapped ADM given in a single i.v. shot at dose of 10 mg kg-'. Groups of mice were sacrificed at days 10, 13, 17, 22 and 26 after tumour inoculation, for examination.
Untreated mice showed after treatment a progressive increase of liver and spleen weights from day 10 after tumour cell injection and of kidney weight from day 15 after tumour cell injection. The weights of the livers of dying mice were between 3.5 and 3.9 g as compared to the normal liver weight which did not exceed 1.4g. The spleen and kidney weights reached respectively 400mg (normal, 110mg) and 650mg (normal, 400 mg). Grossly, there was hepatosplenomegaly with focal areas of tumour involvement noticeable in the liver and sometimes also in the kidneys.
All treated mice showed extensive regression of tumour foci in the liver and spleen. Although the pattern and timing of tumour regression was similar with both treatment modalities, there was a noticeable difference in the extent and duration of the responses observed. As seen in Table II , complete pathologic tumour regression was found in only 2/12 mice treated with free ADM, whereas among L-ADM-treated mice examined in the same period of time, complete pathological remission was present in 9/12 animals. The data of Table II also suggest that the liposome associated drug was effective in preventing or delaying tumour development in the kidneys. Figures 5, 6 and 7 show representative microscopic cross-sections of the livers of untreated, free-ADM-treated and L-ADM-treated mice, 3 days after drug injection. This study did not reveal any significant toxic effects on the normal liver and kidney tissues with either form of treatment. In the spleen, severe inhibition of erythro and myelopoiesis was observed with both types of treatment. Between days 7 and 12 after drug administration haemopoietic function of the spleen was restored to normal.
Discussion
The present study indicates that a significantly increased life prolongation can be obtained using a liposome-associated form of ADM to treat a metastatic tumour with predominant spread to the liver and spleen. Increased antitumour activity of L- ADM on intrahepatic metastases albeit with a phagocytic tumour, has been also shown by . These results are in agreement with our previous data indicating increased intracellular drug levels in liver-residing tumour cells of mice treated with L-ADM as compared to free ADM (Gabizon et al., 1983) . The therapeutic advantage of L-ADM over free ADM rests apparently on a drug concentration effect in the involved tissues, although it remains questionable whether the drug is taken up by tumour cells directly in its liposome-associated form or indirectly after release from liposomes stored by the RES. In this context, the possibility of ADM transfer from macrophages into tumour cells has been reported (Martin et al., 1982) .
The activity of L-ADM appears to be dependent on tumour location in specific anatomic areas accessible to liposomes, such as liver and spleen. This point is emphasized by the reduced effectiveness of L-ADM found in mice with i.m. implanted tumours. The question as to whether anatomical barriers will determine differential access and differential anti-tumour activities of liposome delivered drugs in different body locations has raised objections about the applicability of these carriers in cancer chemotherapy (Poste, 1983) . However, the therapeutic activity of L-ADM on tumour cells infiltrating the liver, spleen and, probably the kidneys, as shown here, is a distinct advantage which may outweight in selected neoplastic conditions a possible reduced activity in other locations.
It has been proposed that liposomes act by providing a slow-release drug depot, improving the pharmacokinetic properties of some drugs (Kaye et al., 1981; Richardson & Ryman, 1982; Mayhew & Papahadjopoulos, 1983) . With phase-specific drugs, such as cytosine arabinoside (Ara-C) and methotrexate, the higher and sustained blood levels appear to account for a superior antitumour activity when compared to free drug bolus injections (Richardson & Ryman, 1982) . Indeed, it has been reported that there is no difference in the therapeutic efficacy comparing a single dose of liposomal Ara-C with a 5-day infusion of free Ara-C in an i.v.-tumour-i.v. treament model . With regard to ADM, the factors regulating the therapeutic index of the liposome associated form seem to be different since it has been recently reported that the therapeutic index of 24 h infused free ADM is still inferior to that of L-ADM (Mayhew & Rustum, 1984) . We have found previously (Gabizon et al., 1982) that the blood levels of ADM are 10-100 times lower than those already detected in the liver and spleen 1 h after injection of ADM entrapped in negatively-charged liposomes. Therefore, it is unlikely that the circulating liposomal drug pool can account for a prolonged exposure of accessible tumour cells to ADM. However, a slow-release effect within the tumour-involved liver may well be important in determining the antitumour effect. In this context. we have shown that the hepatic clearance of ADM is prolonged in mice injected with the liposomal drug (Gabizon et al., 1982) . A similar finding was reported by Kaye et al. (1981) (Goormaghtigh et al., 1980; Gabizon et al., 1982) . Based on these consideration, we chose to carry out the in vivo anti-tumour experiments with liposomes containing either PG or PS as negatively charged phospholipid. As shown in the present study, neither the replacement of PS with PG, nor the reduction of Chol content, significantly affected the anti-tumour effect observed. However, if therapeutic applications of L-ADM are contemplated, PG should be preferred to PS because it is less sensitive to lipid oxidation processes affecting the head group (Roseman et al., 1975) and can be readily obtained from animal sources by a simpler enzymatic conversion of PC (Comfurius & Zwaal, 1977) . The fact that the Chol: phospholipid molar ratio can be decreased to 25% without any significant loss of anti-tumour activity is consistent with the ability of liposomes to withstand the deleterious effect of serum proteins when the Chol content is kept above 20% (Pownall et al., 1979; Snyder & Freire, 1980) . This reduction of Chol content is important as it allows to reduce the lipid load necessary to deliver therapeutic doses of ADM.
In our studies, we have used sonication as a means of obtaining a small sized vesicle population with a reproducible size distribution. Small liposomes (<100 nm) can apparently reach the parenchymal area of the liver to a significant scale (Poste et al., 1982) and are more efficiently incorporated by non-phagocytic cells when compared to large-sized vesicles (Straubinger et al., 1983; Machy & Leserman, 1983; Matthay et al., 1984) , suggesting that they constitute the most advantageous vesicles for in vivo tissue penetrability and delivery of cytotoxic drugs to tumour cells. It is at present unclear whether drug-loaded vesicles of similar size prepared by different methods such as sonication, membrane extrusion, and French press (reviewed by Szoka & Papahadjopoulos, 1980) have the same biological activity.
Obviously, the potential clinical benefit of L-ADM must be evaluated in the light of the reduced acute and chronic toxicities reported with this modality of administration (Rahman et al., 1980 (Rahman et al., , 1982 Forssen & Tokes, 1981; Olson et al., 1982; Herman et al., 1983) . Since the superior antitumour activity of L-ADM in the metastatic model is already apparent at equal doses of free drug, and the LD50 of ADM is significantly increased by liposome association (Olson et al., 1982; Gabizon et al., 1984) , it can be inferred that liposome entrapment improves the therapeutic index of ADM in a selected group of neoplastic conditions. Yet it is not possible to predict at this time, the actual scope of clinical applicability in view of the broad heterogeneity of tumours with regard to factors such as microvascular architecture (Shubik, 1982) , nodular versus diffuse growth, zonal differences in various phenotypic characteristics (Fidler & Hart, 1981) , endocytic uptake of particular material and macrophage infiltration (Talmadge et al., 1981) , all of which may have important implications on accessibility and uptake of liposomes. This work was supported by the Israel National Council for Research and Development.
